Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8393739 | 1.00 | CYP1A2 (0.37) | CYP1A2EPHX1HIF1ASIGMAR1ALDH1A1 | |
| SCHEMBL193152 | 0.97 | — | — | |
| SCHEMBL919602 | 0.92 | — | — | |
| SCHEMBL920032 | 0.86 | — | — | |
| SCHEMBL303718 | 0.85 | CYP1A2 (0.44) | CYP1A2EPHX1HIF1ASIGMAR1ALDH1A1 | |
| SCHEMBL7054446 | 0.83 | SIGMAR1 (0.46) | CYP1A2EPHX1SIGMAR1 | |
| SCHEMBL920855 | 0.82 | CYP1A2 (0.41) | CYP1A2SIGMAR1 | |
| SCHEMBL10444336 | 0.81 | SIGMAR1 (0.49) | CYP1A2EPHX1SIGMAR1 | |
| SCHEMBL9214648 | 0.81 | SIGMAR1 (0.49) | CYP1A2EPHX1SIGMAR1 | |
| SCHEMBL9737302 | 0.81 | SIGMAR1 (0.49) | CYP1A2EPHX1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 517 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1790639-B1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS CXCR4-ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2014-03-26 | — | — | EP | claimed |
| US-20110142856-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-16 | — | — | US | claimed |
| US-7951816-B2 | Compound containing basic group and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-31 | — | — | US | claimed |
| US-20080009495-A1 | Compound Containing Basic Group and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-10 | — | — | US | claimed |
| EP-1790639-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | claimed |
| EP-3244896-B1 | METHODS FOR TREATING PULMONARY HYPERTENSION | REVIVA PHARMACEUTICALS INC (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20230263803-A1 | METHODS OF PREVENTING OR TREATING COVID-19 AND RELATED VIRAL DISEASES OR DISORDERS | KINARUS AG (CH) | 2023-08-24 | — | — | US | disclosed |
| EP-4196120-A1 | METHODS OF PREVENTING OR TREATING COVID-19 AND RELATED VIRAL DISEASES OR DISORDERS | Kinarus AG (CH) | 2023-06-21 | — | — | EP | disclosed |
| US-20230104341-A1 | Hazardous Agent Injection System | ANTARES PHARMA, INC. (US) | 2023-04-06 | — | — | US | disclosed |
| EP-4159212-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-11576916-B2 | Methods of preventing or treating ophthalmic diseases | KINARUS AG (CH) | 2023-02-14 | — | — | US | disclosed |
| US-11365175-B2 | Aromatic amides having a fungicidal activity, their agronomic compositions and relative preparation method | ISAGRO S.P.A. (IT) | 2022-06-21 | — | — | US | disclosed |
| EP-0063826-A2 | 2-Amino-benzoic-acid derivatives, their preparation and their use as medicines or intermediates | Dr. Karl Thomae GmbH (DE) | 1982-11-03 | — | — | EP | disclosed |
| EP-0058779-A2 | Carboxamides, their preparation and their use as medicines | Dr. Karl Thomae GmbH (DE) | 1982-09-01 | — | — | EP | disclosed |
| EP-0046572-A2 | 6-Quinazolinesulfonyl derivatives and process for preparation thereof | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1982-03-03 | — | — | EP | disclosed |
| EP-0034743-A1 | Benzoxazoles, their preparation and their use as medicines | Dr. Karl Thomae GmbH (DE) | 1981-09-02 | — | — | EP | disclosed |
| EP-0026414-A2 | Water soluble monoazo compounds, their preparation and their use as dyestuffs in dyeing and printing textile materials, as well as the amines per se | CIBA-GEIGY AG (CH) | 1981-04-08 | — | — | EP | disclosed |
| EP-0024282-A1 | Benzoyl derivatives, their preparation and their use as medicines | Dr. Karl Thomae GmbH (DE) | 1981-03-04 | — | — | EP | disclosed |
| EP-0023569-A1 | Derivatives of carboxylic acids, their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1981-02-11 | — | — | EP | disclosed |
| US-4182887-A | ANTIPHLOGISTIC, ANTITHROMBOTIC | BOEHRINGER INGELHEIM GMBH (DE) | 1980-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230104341-A1 | Hazardous Agent Injection System | TIAL1, AHSA1, GYS2 | CYP1A2 110/4885EPHX1 56/4885HIF1A 4530/4885 |
| US-11576916-B2 | Methods of preventing or treating ophthalmic diseases | PPARA, PPARG, PPARD | CYP1A2 2355/4885EPHX1 2509/4885HIF1A 1141/4885 |
| US-20230263803-A1 | METHODS OF PREVENTING OR TREATING COVID-19 AND RELATED VIRAL DISEASES OR DISORDERS | PPARA, PPARD, PPARG | CYP1A2 631/4885EPHX1 2357/4885HIF1A 924/4885 |
| US-11365175-B2 | Aromatic amides having a fungicidal activity, their agronomic compositions and relative preparation method | CYP51A1, NAT1, AADAC | CYP1A2 7/4885EPHX1 885/4885HIF1A 3039/4885 |
| US-20110142856-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | CXCR4, CCR5, CXCL12 | CYP1A2 1657/4885EPHX1 825/4885HIF1A 389/4885 |
| US-20080009495-A1 | Compound Containing Basic Group and Use Thereof | CXCR4, CCR5, CXCR3 | CYP1A2 1726/4885EPHX1 792/4885HIF1A 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.